Nurix jumps as investors digest newly announced global Roche partnership for BTK degrader bexobrutideg

Nurix Therapeutics (NRIX) is up 7.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to Nurix’s newly announced global collaboration with Roche around bexobrutideg (NX-5948), its oral BTK degrader. The headline economics (a large upfront payment plus potential milestones) and a broad development plan across oncology, immunology, and neurology likely improved investor expectations for funding runway and long-term commercial potential.

Details:

Nurix disclosed a global collaboration structure with Roche to co-develop and co-commercialize bexobrutideg, expanding the program beyond malignant hematology into additional planned studies in neurology and immunology.

The company stated it will receive $700 million in upfront cash and could earn additional development, regulatory, and sales milestones that bring total potential payments up to $2.3 billion.

Nurix said development costs will be split 40% (Nurix) / 60% (Roche), with profits and losses split equally in the U.S., while Nurix would receive tiered royalties on ex-U.S. sales.

Nurix also scheduled a June 8, 2026 morning investor conference call/webcast to discuss the collaboration, which can amplify near-term trading interest after a major deal announcement.

Sources:

Nurix Therapeutics (IR / press release), Roche (press release), SEC (8-K)

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NRIX Insider Trading Activity

$NRIX insiders have traded $NRIX stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.

Here’s a breakdown of recent trading of $NRIX stock by insiders over the last 6 months:

CHRISTINE RING (Chief Legal Officer) has made 0 purchases and 12 sales selling 67,402 shares for an estimated $1,114,895.
HOUTE HANS VAN (Chief Financial Officer) has made 0 purchases and 5 sales selling 20,104 shares for an estimated $333,834.
GWENN HANSEN (Chief Scientific Officer) has made 0 purchases and 3 sales selling 8,109 shares for an estimated $134,747.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive NRIX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$NRIX Hedge Fund Activity

We have seen 106 institutional investors add shares of $NRIX stock to their portfolio, and 90 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

POINT72 ASSET MANAGEMENT, L.P. removed 2,762,574 shares (-86.0%) from their portfolio in Q1 2026, for an estimated $42,819,897
BRAIDWELL LP added 2,183,864 shares (+inf%) to their portfolio in Q4 2025, for an estimated $41,427,900
PERCEPTIVE ADVISORS LLC added 2,139,728 shares (+151.1%) to their portfolio in Q4 2025, for an estimated $40,590,640
VESTAL POINT CAPITAL, LP added 1,810,000 shares (+38.6%) to their portfolio in Q1 2026, for an estimated $28,055,000
STATE STREET CORP added 1,581,694 shares (+44.4%) to their portfolio in Q1 2026, for an estimated $24,516,257
VANGUARD GROUP INC added 1,460,736 shares (+32.5%) to their portfolio in Q4 2025, for an estimated $27,710,161
FMR LLC added 1,307,113 shares (+30.9%) to their portfolio in Q1 2026, for an estimated $20,260,251

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$NRIX Analyst Ratings

Wall Street analysts have issued reports on $NRIX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 01/29/2026
Needham issued a "Buy" rating on 01/29/2026
Piper Sandler issued a "Overweight" rating on 01/29/2026
Morgan Stanley issued a "Overweight" rating on 01/08/2026
Wells Fargo issued a "Overweight" rating on 12/16/2025

To track analyst ratings and price targets for $NRIX, check out Quiver Quantitative's $NRIX forecast page.

$NRIX Price Targets

Multiple analysts have issued price targets for $NRIX recently. We have seen 8 analysts offer price targets for $NRIX in the last 6 months, with a median target of $31.0.

Here are some recent targets:

Jeet Mukherjee from BTIG set a target price of $30.0 on 05/18/2026
Robert Burns from HC Wainwright & Co. set a target price of $32.0 on 04/27/2026
Gil Blum from Needham set a target price of $26.0 on 04/23/2026
Derek Archila from Wells Fargo set a target price of $28.0 on 04/09/2026
Brian Abrahams from RBC Capital set a target price of $30.0 on 01/29/2026
Stephen Willey from Stifel set a target price of $35.0 on 01/29/2026
Joseph Catanzaro from Piper Sandler set a target price of $35.0 on 01/29/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.